Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

Matthew Gall appointed Chief Financial Officer -- Additional key appointments add expertise in clinical operations, corporate strategy and project leadership - BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced key leadership appointments, adding three seasoned industry executives to the Company to support the rapid advancement o ...